Skip to main content

Table 1 Association between TP53 codon 72 status and clinicopathological characteristics

From: Association of TP53codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients

 

Total, n (percent)

Arg/Arg, n (percent)

Arg/Pro, n (percent)

Arg/Arg +Arg/Pro, n (percent)

Pro/Pro, n (percent)

P a

Patients

557 (100)

63 (11)

281 (51)

344 (62)

213 (38)

 

Age (median, year) (n = 557)

 

55

57

56

58

 

Tumor size (n = 557)

     

0.16

   ≤ 2 cm

202 (36)

17 (27)

99 (35)

116 (33)

86 (40)

 

   2 cm to ≤ 5 cm

286 (51)

37 (59)

151 (54)

188 (55)

98 (46)

 

   >5 cm

57 (10)

6 (9)

28 (10)

34 (10)

23 (11)

 

   Unknown

12 (2)

3 (5)

3 (1)

6 (2)

6 (3)

 

Node status (n = 557)

     

>0.99

   Negative

321 (58)

34 (54)

167 (60)

201 (58)

120 (56)

 

   Positive

198 (35)

25 (40)

99 (35)

124 (36)

74 (35)

 

   Unknown

38 (7)

4 (6)

15 (5)

19 (6)

19 (9)

 

Histology (n = 557)

     

0.98

   IDC

486 (87)

54 (86)

246 (87)

300 (87)

186 (87)

 

   ILC

20 (4)

2 (3)

10 (4)

12 (4)

8 (4)

 

   Others

51 (9)

7 (11)

25 (9)

32 (9)

19 (9)

 

ER status (n = 557)

     

0.13

   Positive

344 (62)

33 (52)

171 (61)

204 (59)

140 (66)

 

   Negative

181 (32)

25 (40)

95 (34)

120 (35)

61 (29)

 

   Unknown

32 (6)

5 (8)

15 (5)

20 (6)

12 (5)

 

Grade (n = 289)

     

0.27

   1

71 (24)

3 (9)

48 (32)

51 (28)

20 (19)

 

   2

147 (51)

21 (62)

67 (45)

89 (48)

59 (56)

 

   3

54 (19)

8 (23)

28 (19)

36 (19)

18 (17)

 

   Unknown

17 (6)

2 (6)

7 (4)

9 (5)

8 (8)

 

p53 IHC (n = 289)

     

>0.99

   Positive

72 (25)

15 (44)

29 (19)

44 (24)

28 (27)

 

   Negative

196 (68)

19 (56)

108 (72)

127 (69)

69 (66)

 

   Unknown

21 (7)

0 (0)

13 (9)

13 (7)

8 (7)

 
  1. aArg/Arg and Arg/Pro genotypes compared with Pro/Pro genotype. ER, estrogen receptor; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; ILC, invasive lobular carcinoma.